TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a neutral rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st. Read Our Latest […]

Leave a Reply

Your email address will not be published.

Previous post STAAR Surgical (NASDAQ:STAA) Price Target Cut to $41.00 by Analysts at Canaccord Genuity Group
Next post Tandem Diabetes Care (NASDAQ:TNDM) Coverage Initiated by Analysts at Canaccord Genuity Group